<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AE7EA01F-0FBC-454A-9BBC-762E455AC90B"><gtr:id>AE7EA01F-0FBC-454A-9BBC-762E455AC90B</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Emrys</gtr:otherNames><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_14101"><gtr:id>039E2DEB-A1B8-4A96-8503-90028C4DB16E</gtr:id><gtr:title>Newcastle University Confidence in Concept 2014</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_14101</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>600000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>146927</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HARMONIzation and integrative analysis of regional, national and international Cohorts on primary Sj&amp;ouml;gren's Syndrome (pSS) towards improved stratification, treatment and health policy making</gtr:description><gtr:end>2020-06-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef> 731944 - HarmonicSS - H2020-SC1-2016-2017/H2020-SC1-2016-RTD</gtr:fundingRef><gtr:id>7B623AEB-ED39-42AA-BB7A-524E78FF84D5</gtr:id><gtr:outcomeId>58c80c072852e1.38051439</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>9792</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Determining the role of TLE3 in beta-cell identity and fate conversion</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Diabetes UK</gtr:fundingOrg><gtr:fundingRef>Application reference:  16/0005434</gtr:fundingRef><gtr:id>05CC4D68-0781-4C6C-8608-DD0D5D8A1663</gtr:id><gtr:outcomeId>58c81042df01f3.04230313</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>22000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developing techniques to decrease 'pro-cancer' versions of HER2 in breast cancer cells</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Gateshead Health NHS Foundation Trust</gtr:fundingOrg><gtr:id>F0134984-AFAE-4CD6-B18C-54BD8135E0CF</gtr:id><gtr:outcomeId>58c8128ca7ea73.61049644</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49967</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>RESi-Sense PRF - IDRIS System: proof of concept and exploration of commercialisation routes</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>B1D97B78-03A2-4F73-88E3-E6C0A63EDE16</gtr:id><gtr:outcomeId>58c81a359bd462.27898955</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>82852</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC IAA Phase 2: Exploiting the translational potential of bioinformatics driven diagnostics development</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>A312CFB7-5F19-4D3A-8292-A0FA8D02F422</gtr:id><gtr:outcomeId>58c819d469d603.39520099</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>21305</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Comparison of mitochondrial bioenergetic analysis techniques for Chronic Fatigue Syndrome / Myalgic Encephalomyelitis diagnosis</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>ME Association</gtr:fundingOrg><gtr:id>E9BD1CEE-12AA-43A7-A431-756D49AAF295</gtr:id><gtr:outcomeId>58c8165f1d0f99.48855039</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>22169</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>OCA on cognitive Symptoms</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Intercept Pharmaceuticals</gtr:fundingOrg><gtr:id>FEBCCF41-0F51-45AE-83B1-510A68772C8B</gtr:id><gtr:outcomeId>5461ee696c0940.99761363</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>17504</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Do the levels of deoxythioguanosine (dTG) in DNA of Autoimmune Hepatitis (AIH) patients with azathioprine correlate with clinica</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>Newcastle upon Tyne Hospitals NHS Charity</gtr:fundingOrg><gtr:id>81CE07CD-1611-4D6D-91C8-C5CF4806E5F5</gtr:id><gtr:outcomeId>58c818b9d88d45.02245239</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>33897</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Evaluating the HER2 status: developing assays to measure different versions of HER2 in breast cancer cells</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Royal Victoria Infirmary</gtr:fundingOrg><gtr:id>99359B13-CE17-409B-B524-E395018E8613</gtr:id><gtr:outcomeId>58c8120e6de148.35217173</gtr:outcomeId><gtr:sector>Hospitals</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>44621</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Testing the hypothesis that LDAA reduces UV-mediated damage to mitochondrial and nuclear DNA compared to AZA</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>The JGW Patterson Foundation</gtr:fundingOrg><gtr:id>BCFCA6D8-AAFC-4B2D-9EA8-F0B157C98E31</gtr:id><gtr:outcomeId>58c817b4e71c31.56447818</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>28398</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Studentship (50%) Anna-Lena Ditrich</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Royal Victoria Infirmary</gtr:fundingOrg><gtr:id>5A5409EE-8D64-477F-9E1F-61631F1FAB62</gtr:id><gtr:outcomeId>58c812e2258aa6.37516349</gtr:outcomeId><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The development of a novel light-sensitive membrane protein that, when activated, drives chloride out of cells. The usefulness of this is that there is considerable evidence that a primary pathology in many types of epilepsy arises from a failure to regulate neuronal chloride levels, leading to the build up of chloride inside cells. Our novel strategy allowed a direct test of this hypothesis and may provide therapeutic avenues.</gtr:description><gtr:grantRef>MC_PC_14101</gtr:grantRef><gtr:id>0FA1818B-59CE-4CBF-BE3E-A34473A729BA</gtr:id><gtr:impact>This work continues to be a major focus of Dr Trevelyan's laboratory. They will continue this work in parallel with the CANDO project, and aim to bring in further research funds to test the strategy for modulating neuronal activity, and in particular epileptic activity, in more sophisticated animal models, including in vivo.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>58c80eddae27c4.54558868</gtr:outcomeId><gtr:patentId>patent number GB1601008.4</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Cl-out: A novel optogenetic protein for removing chloride from neurons</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E82E2B76-CE8A-4BB0-8050-15A342941A40</gtr:id><gtr:title>Liquid chromatography-mass spectrometry for measuring deoxythioguanosine in DNA from thiopurine-treated patients.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/631630314e670d004b103ad92f5aa41d"><gtr:id>631630314e670d004b103ad92f5aa41d</gtr:id><gtr:otherNames>Coulthard SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn><gtr:outcomeId>58c81927629be6.37716201</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5446758-4113-421A-B5F8-F1577B5DDA67</gtr:id><gtr:title>SRSF3 and hnRNP H1 regulate a splicing hotspot of HER2 in breast cancer cells.</gtr:title><gtr:parentPublicationTitle>RNA biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e540b045da557475367f9158fc52d82"><gtr:id>0e540b045da557475367f9158fc52d82</gtr:id><gtr:otherNames>Gautrey H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1547-6286</gtr:issn><gtr:outcomeId>58c81340b66773.49055720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEBDCAE6-66CA-477C-9ECA-381D72AA9394</gtr:id><gtr:title>Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad20b0affb1ad067d0c89b85c200083e"><gtr:id>ad20b0affb1ad067d0c89b85c200083e</gtr:id><gtr:otherNames>Grover VP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>58c14711e65170.70771063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A286E9B3-2984-4628-AE76-8C6DA8145F09</gtr:id><gtr:title>Cl-out is a novel cooperative optogenetic tool for extruding chloride from neurons.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/276db4ccd885c5ba8873611b70adb55c"><gtr:id>276db4ccd885c5ba8873611b70adb55c</gtr:id><gtr:otherNames>Alfonsa H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c80cec610e29.45684098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8F5C727-747C-49BF-8A8A-200690287D92</gtr:id><gtr:title>Varenicline, the clinically effective smoking cessation agent, restores probabilistic response reversal performance during withdrawal from nicotine.</gtr:title><gtr:parentPublicationTitle>Addiction biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cde5a728a30fccb64991e2d25d7a59d"><gtr:id>4cde5a728a30fccb64991e2d25d7a59d</gtr:id><gtr:otherNames>Jackson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1355-6215</gtr:issn><gtr:outcomeId>58c80aebe4ad10.99072664</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_14101</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>